There has been a significant rise in the use of GLP-1 medications in recent years—particularly for weight loss, metabolic health, and blood sugar regulation.
From an osteopathic perspective, this opens an important and nuanced conversation.
Because while these medications can offer powerful support for some patients, they also influence the body in ways that are broader, deeper, and more interconnected than they are often discussed.
GLP-1 (glucagon-like peptide-1) receptor agonists—such as semaglutide—are medications designed to support blood sugar regulation, appetite control, and weight loss.
They work by:
These mechanisms are well supported in clinical research and underpin their effectiveness in both diabetes and weight management (Drucker, 2018; Nauck & Meier, 2019).
There is strong evidence to support the use of GLP-1 medications in certain contexts.
1. Effective weight loss and metabolic change
Large randomised controlled trials (e.g. STEP trials) show significant and sustained weight loss with semaglutide, often in the range of 10–15% or more of body weight (Wilding et al., 2021).
2. Blood sugar regulation
GLP-1 receptor agonists are well established in type 2 diabetes care, improving glycaemic control and reducing HbA1c (Davies et al., 2018).
3. Reduced inflammatory load
Evidence suggests GLP-1 analogues may reduce inflammatory markers such as CRP and IL-6, contributing to systemic benefits (Lee et al., 2021).
4. Cardiovascular benefits
Cardiovascular outcome trials (e.g. LEADER, SUSTAIN-6) demonstrate reduced risk of major adverse cardiovascular events in high-risk populations (Marso et al., 2016; Gerstein et al., 2019).
From an osteopathic perspective, these benefits sit alongside important considerations.
1. Digestive impact
GLP-1 medications delay gastric emptying, which is central to their mechanism but also explains common side effects such as nausea, bloating, and reflux (Nauck et al., 2011).
2. Nutritional intake
Reduced appetite may lead to lower caloric and protein intake, raising concerns about nutritional adequacy—particularly in rapid weight loss contexts (Hall et al., 2022).
3. Nervous system involvement
GLP-1 receptors are present in the brain and vagal pathways, influencing appetite, satiety, and autonomic regulation (Holst, 2007).
4. Rapid weight loss and structural adaptation
Rapid changes in body mass are known to affect musculoskeletal loading and biomechanics, although this is less studied specifically in GLP-1 trials.
Emerging evidence suggests that weight loss associated with GLP-1 medications includes a proportion of lean mass loss.
Studies indicate that approximately 25–40% of weight lost may come from lean tissue, including muscle (Wilding et al., 2021; Heymsfield et al., 2016).
While some lean mass loss is expected in any caloric deficit, this raises important clinical considerations around long-term strength, metabolism, and function.
From an osteopathic and functional perspective, muscle plays a central role in health.
Encouragingly, evidence suggests muscle loss can be mitigated.
Key strategies include:
The body produces GLP-1 endogenously, and several lifestyle factors can enhance its secretion.
1. Protein intake
Protein-rich meals stimulate GLP-1 release and increase satiety (Lejeune et al., 2006).
2. Dietary fibre and gut microbiome
Fermentable fibres increase short-chain fatty acid production, which enhances GLP-1 secretion (Tolhurst et al., 2012).
3. Healthy fats
Dietary fats can stimulate incretin hormones, including GLP-1 (Feltrin et al., 2004).
4. Physical activity
Exercise improves GLP-1 response and metabolic sensitivity (Ueda et al., 2009).
5. Sleep and circadian rhythm
Sleep deprivation disrupts appetite-regulating hormones, including GLP-1 pathways (Spiegel et al., 2004).
6. Eating behaviour
Slower eating enhances satiety signalling and hormonal responses (Andrade et al., 2008).
Osteopathy invites us to ask:
How is the whole system responding?
GLP-1 medications influence:
From this perspective, they are not isolated interventions—but system-wide modulators.
Evidence supports a multidisciplinary, supportive approach to weight loss and metabolic care.
Osteopathic support may include:
GLP-1 medications are:
They are best understood not as a standalone solution, but as part of a broader, integrated approach.
The evidence is clear: GLP-1 medications represent a major advancement in metabolic medicine.
But they also reinforce something fundamental:
The body is not just a metabolic system—it is a dynamic, interconnected whole.
Whether through medication or lifestyle, influencing GLP-1 affects appetite, digestion, muscle, movement, and nervous system balance.
From an osteopathic perspective, the goal is not simply change—but supported change.
Change that preserves strength.
Change that respects the body’s pace.
Change that maintains integrity across the whole system.
Because true health is not defined by weight alone—but by how well the body can function, adapt, and feel at home within itself.
Founder, Osteopath, Shamanic Healer
The Gentle Power of Ceremonial-Grade Cacao: What the Research and Ritual Reveal There’s something sacred in the smooth richness of ceremonial-grade cacao—a mindful way to nourish both body and soul.
Neuroplasticity and Physical Pain: When the Brain Remembers Too Well Pain is often thought of as a straightforward message from the body to the brain—an injury occurs, nerves send signals,
High in the Peruvian Andes — above the clouds, beyond the roads, in deep valleys held sacred by the mountains — live the Q’ero Nation, the last living inheritors of the
In osteopathic and holistic traditions alike, the body is seen as a mirror of balance — physical, emotional, and spiritual. Yet one area that often goes unnoticed in this reflection
